Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Imugene ( (AU:IMU) ).
Imugene Limited has notified the market of the issue of new unquoted options under its existing equity arrangements. The company is issuing a total of 40,906 options, each expiring on 30 June 2028 with an exercise price of $0.86, across three separate allotment dates in March 2026.
These options are not quoted and are not intended to be quoted on the ASX, and they form part of transactions previously flagged in an earlier Appendix 3B. The move modestly expands Imugene’s pool of unlisted equity incentives, which may support ongoing capital management and employee or stakeholder alignment without immediate dilution in the quoted market.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.18 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a biotechnology company listed on the ASX under the code IMU. The company is focused on developing immuno-oncology therapies, leveraging innovative approaches to treat cancer and targeting global healthcare markets.
Average Trading Volume: 1,497,604
Technical Sentiment Signal: Sell
Current Market Cap: A$56.27M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.